Showing 5,807 results

Filters Content type: News, Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Pregnancy and vertical transmission

Another HIV Tivicay Birth Outcome: Better Infant Survival

Editor's pick
Medscape (requires free registration)
15 March 2021
Injectable & long-acting HIV treatment

Injectable HIV medications must be practical and affordable, conference hears

News
15 March 2021
Transgender people

Gender-affirming surgery associated with sustained viral suppression

News
15 March 2021
Contraception

Doubling the dose of emergency contraception is a safe and effective way of overcoming efavirenz interaction

News
15 March 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
Injectable & long-acting HIV treatment

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years

News
12 March 2021
TB treatment

Should TB Treatment Move into Long-Acting Injectables?

Editor's pick
Contagion Live
11 March 2021
PrEP science

HPTN 083: Injectable PrEP can make breakthrough infections hard to detect

News
10 March 2021
New & experimental HIV treatments

HIV capsid inhibitor offers new option for people with highly resistant HIV

News
10 March 2021
Resistance

Resistance testing does not improve viral suppression after first-line failure in South Africa and Uganda

News
9 March 2021
Changing treatment

African study confirms dolutegravir for second-line treatment and supports recycling of tenofovir

News
9 March 2021
Bone & joint problems

Alendronate can prevent bone loss in people starting HIV treatment

News
9 March 2021
Injectable & long-acting PrEP

Reformulated islatravir implant should provide PrEP for over a year

News
9 March 2021
Health monitoring in resource-limited settings

Near point-of-care viral load tests slash waiting times in seven African countries

News
4 March 2021
Vaccinations & immunisations

US: Interim Guidance for COVID-19 and Persons with HIV

Editor's pick
HIV.gov
1 March 2021
Injectable & long-acting HIV treatment

ViiV Seeks FDA Approval for Cabenuva Dosed Every 2 Months for HIV

Editor's pick
Monthly Prescribing Reference
26 February 2021
HIV treatment

Modern ART paints Soweto bright pink to advertise the latest HIV drug

Editor's pick
Daily Maverick
19 February 2021
Treatment simplification strategies

Similar rate of severe clinical outcomes with two drug vs three drug HIV treatment combinations

News
17 February 2021
Sexually transmitted infections prevention

Antibiotics to prevent STIs – for or against?

News
10 February 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
Antibody-based prevention

Why broadly neutralising antibodies might be the next big thing in HIV

Editor's pick
Spotlight
8 February 2021
Injectable & long-acting HIV treatment

Cabenuva, the First Long-Acting Injectable HIV Regimen, Is Here; Now, Who Will Take It?

Editor's pick
TheBody
29 January 2021
Injectable & long-acting PrEP

Once-a-month PrEP pill easily passes its first big test

News
27 January 2021
Antibody-based prevention

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

News
27 January 2021